Financial Daily from THE HINDU group of publications
Wednesday, Jan 11, 2006
Financial Daily from THE HINDU group of publications Wednesday, Jan 11, 2006 |
|
|
|
|
|
|
|
Corporate
-
Alliances & Joint Ventures Marketing - Strategy Ranbaxy inks co-marketing pact with Ferring Intl Our Bureau
New Delhi , Jan 10 RANBAXY Laboratories Ltd has entered into a co-marketing agreement with Ferring International of Switzerland for Desmopressin, which is used in treatment of urology-related disorders. According to a company statement, the drug would be useful for both paediatric and geriatric patients. Desmopressin, an original research product of Ferring International, is available in tablets and sprays, and is currently marketed by the company's subsidiary in India. This new co-marketing arrangement aims to leverage Ranbaxy's significant marketing and distribution strengths to maximise patient coverage within the country. The product will be sold under the brand name Adiuretin. Mr Sanjeev Dani, Regional Director (India and Middle East), Ranbaxy, said: "This is a strategic move by Ranbaxy to in-licence differentiated products for the Indian market." The Ranbaxy scrip closed at Rs 393.75 on the BSE on Tuesday.
More Stories on : Alliances & Joint Ventures | Strategy
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2006, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|